Back to search

Article

ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA

2022-03-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4157ce85-2b7c-58c3-a072-c022f3dadfba
DOI
10.1016/s0735-1097(22)02466-4
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIADOI 10.1016/s0735-1097(22)02466-4
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.Semantic proximity
The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management RecommendationsSemantic proximity
A new dawn for managing dyslipidemias: The era of rna-based therapiesSemantic proximity
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing TherapiesSemantic proximity
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9Semantic proximity
Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): A randomized, double-blind, placebo-controlled trialSemantic proximity
Severe hypertriglyceridemia: Existing and emerging therapiesSemantic proximity
Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor TherapySemantic proximity
Updates in Small Interfering RNA for the Treatment of DyslipidemiasSemantic proximity
Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL CholesterolSemantic proximity
Nucleic Acid–Based Therapies for AtherosclerosisSemantic proximity
Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemiaSemantic proximity
Select a neighboring publication to make it the new centre.